BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins  University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | May 30, 2020
Product Development

The critical path to COVID-19 therapies

The path to safe, effective COVID-19 therapies is crowded and poorly marked. There is an urgent need to fast-track a manageable number of therapies, illuminate every step along the route, and create signposts for research,...
BioCentury | May 29, 2020
Distillery Therapeutics

Treating malaria with auphen, an inhibitor of the host membrane channel AQP3

DISEASE CATEGORY: Infectious disease INDICATION: Malaria Auphen, a small molecule inhibitor of the host membrane channel AQP3, could treat malaria. Primary human hepatocytes infected with Plasmodium vivax had higher levels of AQP3 protein than uninfected...
BioCentury | May 16, 2020
Politics, Policy & Law

New BIO leader McMurry-Heath to focus on patients and innovation

BIO is looking to its new CEO and President, Michelle McMurry-Heath, to serve as a new face and voice for the industry, and to refocus the organization on patients and on creating the innovations they...
BioCentury | May 15, 2020
Translation in Brief

Passage’s mouse, dog data for Krabbe disease; plus a predictive model of COVID-19 mortality, Sorrento’s COVID-19 antibody candidate and more

Efficacy for Passage’s Krabbe disease gene therapy  Passage Bio Inc. (NASDAQ:PASG) has presented data supporting an IND it plans to submit next half for PBKR03 to treat Krabbe disease. In mouse and dog models of...
BioCentury | May 14, 2020
Politics, Policy & Law

By selecting McMurry-Heath as new leader, BIO breaks mold

BIO has picked a new president and CEO, Michelle McMurry-Heath, who breaks the Washington trade association mold. She will take over on June 1 from Jim Greenwood, who has held the position since 2004; she...
BioCentury | May 14, 2020
Politics, Policy & Law

Manufacturing limits spark fears of COVID-19 vaccine nationalism

There is broad agreement on the importance of creating policies to determine which countries will receive COVID-19 vaccines, but little concurrence on what those policies should be or how they will be created. On Wednesday,...
BioCentury | May 8, 2020
Product Development

Getting real about COVID-19 data with Amy Abernethy and Mark McClellan

Responding to COVID-19 is forcing regulators, medical product developers and health systems to get real about real-world data and evidence as they reach for every available tool to learn about the disease and speed the...
BioCentury | Apr 24, 2020
Product Development

Accelerating the collection of real-world data about COVID-19

If there are silver linings to the COVID-19 crisis, one is the way groups and individuals who often have adversarial or competitive relationships are joining together to fight a common threat. Another is the acceleration...
BioCentury | Apr 24, 2020
Product Development

Stakeholders call for trial standardization as COVID-19 study influx burdens the system

The clinical trial infrastructure for COVID-19 is creating an unsustainable burden on regulators, physicians and patients. Changing the story will require centralized data collection, harmonization across study endpoints and implementation of master protocols, according to...
Items per page:
1 - 10 of 653
BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins  University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | May 30, 2020
Product Development

The critical path to COVID-19 therapies

The path to safe, effective COVID-19 therapies is crowded and poorly marked. There is an urgent need to fast-track a manageable number of therapies, illuminate every step along the route, and create signposts for research,...
BioCentury | May 29, 2020
Distillery Therapeutics

Treating malaria with auphen, an inhibitor of the host membrane channel AQP3

DISEASE CATEGORY: Infectious disease INDICATION: Malaria Auphen, a small molecule inhibitor of the host membrane channel AQP3, could treat malaria. Primary human hepatocytes infected with Plasmodium vivax had higher levels of AQP3 protein than uninfected...
BioCentury | May 16, 2020
Politics, Policy & Law

New BIO leader McMurry-Heath to focus on patients and innovation

BIO is looking to its new CEO and President, Michelle McMurry-Heath, to serve as a new face and voice for the industry, and to refocus the organization on patients and on creating the innovations they...
BioCentury | May 15, 2020
Translation in Brief

Passage’s mouse, dog data for Krabbe disease; plus a predictive model of COVID-19 mortality, Sorrento’s COVID-19 antibody candidate and more

Efficacy for Passage’s Krabbe disease gene therapy  Passage Bio Inc. (NASDAQ:PASG) has presented data supporting an IND it plans to submit next half for PBKR03 to treat Krabbe disease. In mouse and dog models of...
BioCentury | May 14, 2020
Politics, Policy & Law

By selecting McMurry-Heath as new leader, BIO breaks mold

BIO has picked a new president and CEO, Michelle McMurry-Heath, who breaks the Washington trade association mold. She will take over on June 1 from Jim Greenwood, who has held the position since 2004; she...
BioCentury | May 14, 2020
Politics, Policy & Law

Manufacturing limits spark fears of COVID-19 vaccine nationalism

There is broad agreement on the importance of creating policies to determine which countries will receive COVID-19 vaccines, but little concurrence on what those policies should be or how they will be created. On Wednesday,...
BioCentury | May 8, 2020
Product Development

Getting real about COVID-19 data with Amy Abernethy and Mark McClellan

Responding to COVID-19 is forcing regulators, medical product developers and health systems to get real about real-world data and evidence as they reach for every available tool to learn about the disease and speed the...
BioCentury | Apr 24, 2020
Product Development

Accelerating the collection of real-world data about COVID-19

If there are silver linings to the COVID-19 crisis, one is the way groups and individuals who often have adversarial or competitive relationships are joining together to fight a common threat. Another is the acceleration...
BioCentury | Apr 24, 2020
Product Development

Stakeholders call for trial standardization as COVID-19 study influx burdens the system

The clinical trial infrastructure for COVID-19 is creating an unsustainable burden on regulators, physicians and patients. Changing the story will require centralized data collection, harmonization across study endpoints and implementation of master protocols, according to...
Items per page:
1 - 10 of 653